These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27323337)

  • 41. Insulin Resistance in Nondiabetic Peritoneal Dialysis Patients: Associations with Body Composition, Peritoneal Transport, and Peritoneal Glucose Absorption.
    Bernardo AP; Oliveira JC; Santos O; Carvalho MJ; Cabrita A; Rodrigues A
    Clin J Am Soc Nephrol; 2015 Dec; 10(12):2205-12. PubMed ID: 26507143
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes.
    Mojiminiyi OA; Abdella NA; Al Arouj M; Ben Nakhi A
    Int J Obes (Lond); 2007 Feb; 31(2):213-20. PubMed ID: 16755284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcium plus vitamin D supplementation affects glucose metabolism and lipid concentrations in overweight and obese vitamin D deficient women with polycystic ovary syndrome.
    Asemi Z; Foroozanfard F; Hashemi T; Bahmani F; Jamilian M; Esmaillzadeh A
    Clin Nutr; 2015 Aug; 34(4):586-92. PubMed ID: 25300649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Maffioli P
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Which obesity index best explains the link between adipokines, coronary heart disease risk and metabolic abnormalities in type 2 diabetes mellitus?
    Mojiminiyi OA; Al Mulla F; Abdella NA
    Med Princ Pract; 2009; 18(2):123-9. PubMed ID: 19204431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HOMA-estimated insulin resistance is associated with hypertension in Iranian diabetic and non-diabetic subjects.
    Esteghamati A; Khalilzadeh O; Abbasi M; Nakhjavani M; Novin L; Esteghamati AR
    Clin Exp Hypertens; 2008 Jul; 30(5):297-307. PubMed ID: 18633753
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects.
    Matsuhisa M; Yamasaki Y; Emoto M; Shimabukuro M; Ueda S; Funahashi T; Matsuzawa Y
    Diabetes Res Clin Pract; 2007 Jul; 77(1):151-4. PubMed ID: 17081646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial.
    Wilson SR; Scirica BM; Braunwald E; Murphy SA; Karwatowska-Prokopczuk E; Buros JL; Chaitman BR; Morrow DA
    J Am Coll Cardiol; 2009 Apr; 53(17):1510-6. PubMed ID: 19389561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Revascularization Rates and Associated Costs in Patients With Stable Ischemic Heart Disease Initiating Ranolazine Versus Traditional Antianginals as Add-on Therapy.
    Meyer N; Tran O; Hartsfield C; Nguyen L; Kazi DS; Koch B
    Am J Cardiol; 2019 May; 123(10):1602-1609. PubMed ID: 30832963
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME).
    Gentry JL; Mentz RJ; Hurdle M; Wang A
    J Am Coll Cardiol; 2016 Oct; 68(16):1815-1817. PubMed ID: 27737749
    [No Abstract]   [Full Text] [Related]  

  • 53. Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study.
    Nusca A; Bernardini F; Mangiacapra F; Maddaloni E; Melfi R; Ricottini E; Piccirillo F; Manfrini S; Ussia GP; Grigioni F
    J Diabetes Res; 2021; 2021():4952447. PubMed ID: 35005029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of Ranolazine for the Treatment of Coronary Microvascular Dysfunction.
    Sharp RP; Patatanian E; Sirajuddin R
    Am J Cardiovasc Drugs; 2021 Sep; 21(5):513-521. PubMed ID: 33438139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ranolazine: A potential treatment for refractory neuropathic pain.
    Gould HJ; Diamond I
    J Neurol Sci; 2016 Oct; 369():310-311. PubMed ID: 27653915
    [No Abstract]   [Full Text] [Related]  

  • 56. Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study.
    Finch KT; Stratton EA; Farber HW
    J Heart Lung Transplant; 2016 Nov; 35(11):1370-1373. PubMed ID: 27623099
    [No Abstract]   [Full Text] [Related]  

  • 57. Ranolazine for rhythm control in atrial fibrillation: A systematic review and meta-analysis.
    Guerra F; Romandini A; Barbarossa A; Belardinelli L; Capucci A
    Int J Cardiol; 2017 Jan; 227():284-291. PubMed ID: 27839812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of ranolazine in the prevention and treatment of atrial fibrillation: A meta-analysis of randomized clinical trials.
    Gong M; Zhang Z; Fragakis N; Korantzopoulos P; Letsas KP; Li G; Yan GX; Liu T
    Heart Rhythm; 2017 Jan; 14(1):3-11. PubMed ID: 27746384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ranolazine as a novel therapy for pulmonary arterial hypertension.
    Gong M; Fragakis N; Zhang C; Zhang Z; Li G; Liu T
    Int J Cardiol; 2016 Nov; 223():860-862. PubMed ID: 27580221
    [No Abstract]   [Full Text] [Related]  

  • 60. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
    Vitulo P; Stanziola A; Confalonieri M; Libertucci D; Oggionni T; Rottoli P; Paciocco G; Tuzzolino F; Martino L; Beretta M; Callari A; Amaducci A; Badagliacca R; Poscia R; Meloni F; Refini RM; Geri P; Baldi S; Ghio S; D'Alto M; Argiento P; Sofia M; Guardamagna M; Pezzuto B; Vizza CD
    J Heart Lung Transplant; 2017 Feb; 36(2):166-174. PubMed ID: 27329400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.